Want to see HK:6821 full AI Analyst Report?
Top Page
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
(6821)
Select Model
Select Model
Rating:71Outperform
Price Target:
HK$120.00
â–˛(62.60% Upside)
Action:Upgraded
Date:07/01/26
The score is driven primarily by strong financial quality—especially the very low-leverage balance sheet and solid (though normalized) profitability—supported by a positive technical trend with the price above major moving averages. The main drag is valuation, as the high P/E and modest dividend yield imply elevated expectations, while weaker recent free cash flow conversion adds a key financial watch item.
Positive Factors
Very low leverage / strong balance sheet
Extremely low debt and a large equity base provide durable financial flexibility. This reduces bankruptcy risk, supports multi-year investments in GMP capacity and process development, and gives management optionality to pursue contracts or capex without heavy refinancing pressure.
Negative Factors
Weak free cash flow conversion
Thin FCF relative to net income and negative recent FCF growth reduce internal funds available for capex, dividends, or buybacks. Over months this constrains funding for growth initiatives and increases reliance on external financing or equity, limiting strategic flexibility.
Read all positive and negative factors
Positive Factors
Negative Factors
Very low leverage / strong balance sheet
Extremely low debt and a large equity base provide durable financial flexibility. This reduces bankruptcy risk, supports multi-year investments in GMP capacity and process development, and gives management optionality to pursue contracts or capex without heavy refinancing pressure.
Read all positive factors
Asymchem Laboratories (Tianjin) Co., Ltd. Class H (6821) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$66.94B
Dividend Yield1.57%
Average Volume (3M)640.69K
Price to Earnings (P/E)49.3
Beta (1Y)1.28
Revenue Growth18.78%
EPS Growth12.65%
CountryHK
Employees9,595
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)3.08
Shares Outstanding27,834,510
10 Day Avg. Volume442,016
30 Day Avg. Volume640,687
Financial Highlights & Ratios
PEG Ratio1.08
Price to Book (P/B)1.29
Price to Sales (P/S)3.40
P/FCF Ratio165.39
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$129.97Price Target Upside76.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)4.45
Revenue Forecast (FY)HK$9.22B
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Business Overview & Revenue Model
Company Description
Asymchem Laboratories (Tianjin) Co., Ltd. functions as a Contract Development and Manufacturing Organization (CDMO), offering its services to clients across Mainland China and internationally. The company delivers extensive drug research, developm...
How the Company Makes Money
The company primarily makes money by delivering fee-based contract services to pharmaceutical and biotechnology clients. Key revenue streams typically include: (1) Contract Development (CDMO/CRDMO) fees for process development activities such as s...
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Financial Statement Overview
Summary
Income Statement
72
Positive
Balance Sheet
90
Very Positive
Cash Flow
58
Neutral
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.90B | 6.67B | 5.80B | 7.83B | 10.26B | 4.64B |
| Gross Profit | 2.87B | 2.80B | 2.46B | 4.00B | 4.86B | 2.06B |
| EBITDA | 1.27B | 1.85B | 1.58B | 3.03B | 4.08B | 1.41B |
| Net Income | 1.11B | 1.13B | 948.95M | 2.27B | 3.30B | 1.07B |
Balance Sheet | ||||||
| Total Assets | 20.70B | 20.28B | 19.29B | 19.77B | 18.24B | 15.16B |
| Cash, Cash Equivalents and Short-Term Investments | 7.78B | 7.44B | 7.33B | 9.02B | 7.44B | 6.64B |
| Total Debt | 238.99M | 256.47M | 282.53M | 118.71M | 138.35M | 434.49M |
| Total Liabilities | 2.74B | 2.63B | 2.43B | 2.26B | 2.54B | 2.55B |
| Stockholders Equity | 17.95B | 17.64B | 16.85B | 17.48B | 15.65B | 12.61B |
Cash Flow | ||||||
| Free Cash Flow | 120.37M | 137.22M | 124.33M | 2.31B | 1.14B | -1.55B |
| Operating Cash Flow | 1.50B | 1.41B | 1.25B | 3.55B | 3.29B | 113.15M |
| Investing Cash Flow | -1.42B | -633.20M | -1.18B | -2.69B | -4.67B | -2.21B |
| Financing Cash Flow | -345.47M | -344.83M | -1.93B | -542.03M | -742.53M | 6.21B |
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Technical Analysis
Positive
73.80
Price Trends
97.26
Positive
90.33
Positive
87.50
Positive
Market Momentum
5.68
Negative
64.86
Neutral
64.26
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6821, the sentiment is Positive. The current price of 73.8 is below the 20-day moving average (MA) of 97.99, below the 50-day MA of 97.26, and below the 200-day MA of 87.50, indicating a bullish trend. The MACD of 5.68 indicates Negative momentum. The RSI at 64.86 is Neutral, neither overbought nor oversold. The STOCH value of 64.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HK:6821.
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
71 Outperform | HK$66.94B | 49.26 | 6.34% | 1.57% | 18.78% | 12.65% | |
68 Neutral | HK$55.46B | 30.32 | 11.22% | 1.04% | 16.83% | -8.65% | |
64 Neutral | HK$155.62B | 26.08 | 10.64% | ― | 16.79% | 47.14% | |
54 Neutral | HK$29.63B | -6.66 | -12.72% | ― | 60.96% | -117.64% | |
52 Neutral | HK$2.00B | 37.09 | 1.98% | ― | 0.61% | 766.67% | |
52 Neutral | HK$2.61B | 10.34 | 5.57% | ― | -12.90% | 33.65% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
HK:6821
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
118.70
37.08
45.43%
HK:1548
Genscript Biotech
13.61
-1.49
-9.87%
HK:2269
Wuxi Biologics (Cayman)
37.56
11.36
43.36%
HK:3759
Pharmaron Beijing Co., Ltd. Class H
19.52
2.92
17.59%
HK:1521
Frontage Holdings Corp.
0.98
-0.10
-9.26%
HK:1873
Viva Biotech Holdings
1.25
-0.17
-11.97%
Asymchem Laboratories (Tianjin) Co., Ltd. Class H Corporate Events
Asymchem Aligns H Share Register Closure for Dividend and Shareholder Meetings
Jun 25, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has clarified administrative details around its final dividend for the year ended 31 December 2025 and shareholder meeting arrangements. The company is synchronizing the closure period of its H share regis...
Asymchem Calls 2026 EGM to Revise Share Incentives and Governance Policies
Jun 18, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has convened its second extraordinary general meeting of 2026 for 10 July in Tianjin, inviting eligible H shareholders on the Hong Kong register to attend and vote. The meeting will address a proposed repu...
Asymchem Sets July 2026 H Shareholders’ Meeting to Vote on Share Repurchase and Governance Changes
Jun 18, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has called its third H shares class meeting of 2026 to be held on July 10, 2026 in Tianjin, immediately after its second extraordinary general meeting and third A shares class meeting. The session will con...
Asymchem to Repurchase and Cancel Restricted A Shares After Staff Resignations
Jun 17, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has approved the repurchase and cancellation of 117,500 restricted A shares granted under its 2025 A Share restricted share incentive scheme, following the resignation of 15 non-connected incentive partici...
Asymchem adjusts articles to reflect share cancellation and registered capital cut
Jun 17, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has proposed amendments to its articles of association to reflect a reduction in registered capital following the repurchase and cancellation of part of the restricted A shares granted under its 2025 A sha...
Asymchem cancels 94,000 restricted A shares after staff departures
Jun 12, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has completed the repurchase and cancellation of 94,000 restricted A shares granted under its 2025 A Share restricted share incentive scheme, following the resignation of 13 incentive participants. As a re...
Asymchem Reports Voting Outcomes for 2025 AGM and 2026 Share Class Meetings
Jun 10, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. reported the poll results of its 2025 annual general meeting, along with the second class meetings for both its A shares and H shares for 2026, held on 10 June 2026 in Tianjin. The meetings were conducted ...
Asymchem Updates Final 2025 Dividend Terms and Withholding Tax for H-Shareholders
Jun 10, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has declared a final ordinary cash dividend of RMB 13 per 10 shares for the financial year ended 31 December 2025, with shareholder approval granted on 10 June 2026. For Hong Kong holders of H shares, the ...
Asymchem Updates 2025 Final Dividend Terms and Tax Treatment for H-Share Investors
May 15, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed pharma and biotech services provider, offers contract research and manufacturing support to global drug developers. The company operates through H shares in Hong Kong, giving offshore a...
Asymchem Sets 2025 AGM to Approve Dividend Plan and Share Mandates
May 15, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. has called its 2025 annual general meeting for 10 June 2026 in Tianjin, where shareholders will review the 2025 annual report, board work report, financial statements, profit distribution plan and auditors...
Asymchem Calls 2026 H Shareholders’ Meeting to Approve A-Share Buyback Mandate
May 15, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed contract development and manufacturing organization for the pharmaceutical sector, provides laboratory and production services that support drug discovery and commercialization for clie...
Asymchem Q1 2026 Revenue Rises but Profit Edges Lower
Apr 27, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. reported its unaudited first-quarter 2026 results, showing operating revenue of RMB 1.80 billion, up 16.91% year-on-year, while net profit attributable to shareholders fell 6.82% to RMB 304 million and ear...
Asymchem Discloses 2026 Shareholder Meeting Poll Results for A and H Classes
Apr 17, 2026
Asymchem Laboratories (Tianjin) Co., Ltd. reported the poll results of its first extraordinary general meeting of 2026, along with separate class meetings for A shareholders and H shareholders, all held on 17 April 2026 in Tianjin. The meetings we...
Asymchem Schedules Board Meeting to Approve First-Quarter 2026 Results
Apr 13, 2026
Asymchem Laboratories (Tianjin) Co., Ltd., a Hong Kong-listed PRC joint stock company in the pharmaceutical and chemical services industry, operates through subsidiaries to deliver contract research and manufacturing solutions to drug developers. ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.